Azione SANA SANA BIOTECHNOLOGY, INC.
Aggiungi a un elenco
Solo clienti o iscritti possono usare questa funzione
AccediRegistrati

Altre lingue Sana Biotechnology, Inc.

Azioni

SANA

US7995661045

Tempo reale stimato Cboe BZX
Altri mercati azionari
 21:16:39 11/07/2024 		Variaz. 5gg Var. 1 gen.
5,575 USD +7,63% Grafico intraday di Sana Biotechnology, Inc. +10,71% +38,11%
10/06 Transcript : Sana Biotechnology, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 02:40 PM
21/05 Sana Biotechnology, Inc. sottolinea la pubblicazione su Nature Biotechnology di dati preclinici in vivo che dimostrano il potenziale del trapianto di cellule progenitrici gliali umane derivate da cellule staminali pluripotenti come trattamento per la malattia di Huntington e altre condizioni neurodegenerative basate sulla glia. CI

Altre lingue

Ricerca
Vedi i risultati
Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!
Registrazione 100% gratuita
Flagship Pioneering Expands Leadership Team with Key Appointments and Promotions
Flagship Pioneering Raises $3.6 Billion to Fuel Breakthrough Innovations that Transform Human Health and Sustainability
Sana Biotechnology, Inc.(NasdaqGS:SANA) dropped from Russell Small Cap Comp Value Index
Sana Biotechnology, Inc.(NasdaqGS:SANA) dropped from Russell 3000 Value Index
Sana Biotechnology, Inc.(NasdaqGS:SANA) dropped from Russell 2500 Value Index
Sana Biotechnology, Inc.(NasdaqGS:SANA) dropped from Russell 2000 Value Index
Sana Biotechnology, Inc.(NasdaqGS:SANA) dropped from Russell 3000E Value Index
Flagship Pioneering and ProFound Therapeutics Announce Agreement to Identify Novel First-in-Class Therapeutics for the Treatment of Obesity under Strategic Partnership with Pfizer
Sana Biotechnology Highlights Publication in Nature Biotechnology of Novel In Vivo Preclinical Data Showing the Potential for Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Transplantation as a Treatment for Huntington’s Disease and Other Glial-based Neurodegenerative Conditions
Sana Biotechnology, Inc. Highlights Publication in Nature Biotechnology of Novel in Vivo Preclinical Data Showing the Potential for Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Transplantation as A Treatment for Huntington's Disease and Other Glial-Based Neurodegenerative Conditions
Sana: Q1 Earnings Snapshot
Sana Biotechnology Reports First Quarter 2024 Financial Results and Business Updates
Sana Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Sana Biotechnology to Present at May and June 2024 Investor Conferences
Sana Biotechnology, Inc. Announces Resignation of Douglas Williams as Executive Vice President and President, Research and Development
Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences
Certain Restricted Stock Units of Sana Biotechnology, Inc. are subject to a Lock-Up Agreement Ending on 9-APR-2024.
Certain Stock Options of Sana Biotechnology, Inc. are subject to a Lock-Up Agreement Ending on 9-APR-2024.
Certain Common Stock of Sana Biotechnology, Inc. are subject to a Lock-Up Agreement Ending on 9-APR-2024.
Sana Biotechnology Shares Rise as Q4 Non-GAAP Net Loss Narrows
Non ci sono risultati per questa ricerca
Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Filtri

Cerca

Data di pubblicazione

Da

A

  1. Borsa valori
  2. Azioni
  3. Azione SANA
  4. Notizie Sana Biotechnology, Inc.
  5. Altre lingue